CoImmune, Inc.
2 articles with CoImmune, Inc.
-
CoImmune, Inc. Appoints Michael Fekete and Greg Tibbitts to its Board of Directors
7/6/2021
CoImmune, Inc., a clinical stage immuno-oncology company that will redefine cancer treatment using best-in-class yet more affordable cellular immunotherapies, today announced the appointments of Michael Fekete and Greg Tibbitts, to the Company’s board of directors.
-
CoImmune, Inc. Announces Appointment of Ed Baracchini to Board of Directors
2/24/2021
CoImmune, Inc., a clinical stage immuno-oncology company developing cell-based therapeutics to treat unmet medical needs in blood-borne and solid tumor indications, today announced the appointment of Dr. Edgardo Baracchini, to the Company’s board of directors.